Wealth Enhancement Advisory Services LLC Has $112,000 Holdings in Editas Medicine, Inc. $EDIT

Wealth Enhancement Advisory Services LLC lifted its holdings in Editas Medicine, Inc. (NASDAQ:EDIT) by 13.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,105 shares of the company’s stock after acquiring an additional 6,088 shares during the quarter. Wealth Enhancement Advisory Services LLC owned approximately 0.06% of Editas Medicine worth $112,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of EDIT. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Editas Medicine by 122.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,600,000 shares of the company’s stock worth $3,016,000 after acquiring an additional 1,430,000 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Editas Medicine by 288.5% in the 1st quarter. Acadian Asset Management LLC now owns 752,162 shares of the company’s stock worth $869,000 after acquiring an additional 558,567 shares in the last quarter. XTX Topco Ltd boosted its holdings in shares of Editas Medicine by 352.5% in the 1st quarter. XTX Topco Ltd now owns 475,381 shares of the company’s stock worth $551,000 after acquiring an additional 370,325 shares in the last quarter. Nuveen LLC acquired a new position in shares of Editas Medicine in the 1st quarter worth approximately $367,000. Finally, Ieq Capital LLC boosted its holdings in shares of Editas Medicine by 551.0% in the 1st quarter. Ieq Capital LLC now owns 160,370 shares of the company’s stock worth $186,000 after acquiring an additional 135,736 shares in the last quarter. 71.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $5.00 price objective on shares of Editas Medicine in a research report on Friday, September 5th. Wall Street Zen upgraded shares of Editas Medicine from a “sell” rating to a “hold” rating in a research report on Friday, September 26th. Robert W. Baird boosted their price objective on shares of Editas Medicine from $4.00 to $6.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 13th. Wells Fargo & Company boosted their price objective on shares of Editas Medicine from $3.00 to $4.00 and gave the stock an “equal weight” rating in a research report on Wednesday, September 3rd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Editas Medicine in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, seven have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $5.10.

Editas Medicine Stock Down 8.8%

Shares of EDIT stock opened at $3.72 on Monday. Editas Medicine, Inc. has a 12-month low of $0.91 and a 12-month high of $4.54. The firm has a market capitalization of $334.50 million, a price-to-earnings ratio of -1.31 and a beta of 2.18. The firm has a fifty day moving average of $2.94 and a 200-day moving average of $2.28.

Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.22). Editas Medicine had a negative net margin of 608.88% and a negative return on equity of 200.25%. The firm had revenue of $3.58 million during the quarter, compared to analyst estimates of $1.81 million. Research analysts expect that Editas Medicine, Inc. will post -2.71 earnings per share for the current year.

Editas Medicine Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.